Items where authors include "Bharmal, M."

Article

Hatswell, A.J., Bullement, A. orcid.org/0000-0001-7091-0972, Schlichting, M. et al. (1 more author) (2021) What is the impact of the analysis method used for health state utility values on QALYs in oncology? A simulation study comparing progression-based and time-to-death approaches. Applied Health Economics and Health Policy, 19 (3). pp. 389-401. ISSN 1175-5652

Bullement, A. orcid.org/0000-0001-7091-0972, Willis, A., Amin, A. et al. (3 more authors) (2020) Evaluation of survival extrapolation in immuno-oncology using multiple pre-planned data cuts: learnings to aid in model selection. BMC Medical Research Methodology, 20. 103. ISSN 1471-2288

Kapetanakis, V., Prawitz, T., Schlichting, M. et al. (6 more authors) (2019) Assessment-schedule matching in unanchored indirect treatment comparisons of progression-free survival in cancer studies. PharmacoEconomics, 37 (12). pp. 1537-1551. ISSN 1170-7690

Bullement, A. orcid.org/0000-0001-7091-0972, Nathan, P., Willis, A. et al. (6 more authors) (2019) Cost effectiveness of Avelumab for metastatic Merkel cell carcinoma. PharmacoEconomics - Open, 3 (3). pp. 377-390. ISSN 2509-4262

Proceedings Paper

Hatswell, A.J., Bullement, A. orcid.org/0000-0001-7091-0972, Schlichting, M. et al. (1 more author) (2019) PCN259 Should health state utility values (HSUVS) in cancer immunotherapies (IOS) be analyzed by time to death (TTD) or progression status? Results of a simulation study. In: Value in Health. ISPOR 2019 : Rapid. Disruptive. Innovative: A New Era in HEOR, 18-22 May 2019, New Orleans, LA, USA. Elsevier BV , S105-S105.

Bharmal, M., Amin, A., Stapelkamp, C. et al. (5 more authors) (2018) Cost-effectiveness (CE) of avelumab vs standard care (SC) for the treatment of patients (pts) with metastatic Merkel cell carcinoma (mMCC). In: Annals of Oncology. 43rd ESMO Congress (ESMO 2018), 19-23 Oct 2018, Munich, Germany. Elsevier , p. 461.

Bullement, A. orcid.org/0000-0001-7091-0972, Amin, A., Stapelkamp, C. et al. (5 more authors) (2018) Modelling overall survival in immunotherapy using parametric techniques : Avelumab in previously treated metastatic Merkel cell carcinoma. In: Value in Health. ISPOR 21st Annual European Meeting, 10-14 Nov 2018, Barcelona, Spain. Elsevier , S11-S11.

Bullement, A. orcid.org/0000-0001-7091-0972, D'Angelo, S.P., Amin, A. et al. (5 more authors) (2018) Predicting overall survival in patients (pts) with treatment-naive metastatic Merkel cell carcinoma (mMCC) treated with avelumab. In: Journal of Clinical Oncology. 2018 ASCO Annual Meeting, 01-05 Jun 2018, Chicago, IL, USA. American Society of Clinical Oncology .

Hatswell, A.J., Cooper, M., Bharmal, M. et al. (1 more author) (2017) Predicting outcomes from multiple uncontrolled historical studies of standard care – progression-free survival and overall survival in untreated metastatic Merkel cell carcinoma. In: Value in Health. ISPOR 20th Annual European Congress, 04-08 Nov 2017, Glasgow, Scotland. Elsevier , A422.